EMEA-002117-PIP01-17

Key facts

Active substance
Pevonedistat
Therapeutic area
Oncology
Decision number
P/0054/2018
PIP number
EMEA-002117-PIP01-17
Pharmaceutical form(s)
Concentrate for solution for injection/infusion
Condition(s) / indication(s)
  • Treatment of myelodysplastic syndromes (MDS)
  • Treatment of acute myeloid leukaemia (AML)
Route(s) of administration
Intravenous use
Contact for public enquiries
Takeda Pharma A/S
Tel. +44 020 31168000
E-mail: paediatrics@tgrd.com
Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating